セッション

Effect of prior lines of therapy and treatment exposure on Daratumumab with Rd in RRMM: POLLUX

[演者] Torben Plesner:1
[著者] Meletios A. Dimopoulos:2, Paul Richardson:3, James Morton:4, Naoki Takezako:5, Kihyun Kim:6, Christopher Chiu:7, Kaida Wu:7, Xiang Qin:7, Jordan Schecter:8, Jesus San-Miguel:9
1:Vejle Hospital and University of Southern Denmark, Denmark, 2:National and Kapodistrian University of Athens, Athens, Greece, 3:Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, 4:Icon Cancer Care, South Brisbane, QLD, Australia, 5:Department of Hematology, National Hospital Organization Disaster Medical Center of Japan, Tachikawa, Japan, 6:Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 7:Janssen Research & Development, LLC, Spring House, PA, USA, 8:Janssen Research & Development, LLC, Raritan, NJ, USA, 9:Clinica Universidad de Navarra-CIMA, IDISNA, Pamplona, Spain

Daratumumab combined with Rd versus Rd alone for RRMM (POLLUX): Efficacy and safety update

[演者] Kenshi Suzuki:1
[著者] Hareth Nahi:2, P. Joy Ho:3, Shinsuke Iida:4, Miles Prince:5, Jin Seok Kim:6, Christopher Chiu:7, Kaida Wu:7, Xiang Qin:7, Jordan Schecter:8, Philippe Moreau:9
1:Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan, 2:Karolinska Institute and the Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden, 3:Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia, 4:Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 5:University of Melbourne, Peter MacCallum Cancer Centre, Melbourne, Australia, 6:Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea, 7:Janssen Research & Development, LLC, Spring House, PA, USA, 8:Janssen Research & Development, LLC, Raritan, NJ, USA, 9:Hematology, University Hospital Hotel-Dieu, Nantes, France

Japanese subanalysis of ELOQUENT-2: 4-y follow-up of Elotuzumab + Len/Dex for multiple myeloma (MM)

[演者] Hiroshi Handa (半田 寛):1
[著者] Kazutaka Sunami (角南 一貴):2, Kenshi Suzuki (鈴木 憲史):3, Kazuteru Ohashi (大橋 一輝):4, Shinsuke Iida (飯田 真介):5, Shinichiro Okamoto (岡本 真一郎):6, Kosei Matsue (末永 孝生):7, Masafumi Miyoshi (三好 昌史):8, Eric Bleickardt:9, Morio Matsumoto (松本 守生):10, Masafumi Taniwaki (谷脇 雅史):11
1:Division of Hematology, Gunma University Hospital, Maebashi, Japan, 2:Okayama Medical Center, Okayama, Japan, 3:Japanese Red Cross Medical Center, Tokyo, Japan, 4:Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, 5:Nagoya City University Hospital, Nagoya, Japan, 6:Keio University Hospital, Tokyo, Japan, 7:Kameda Medical Center, Kamogawa, Japan, 8:Bristol-Myers Squibb K.K., Tokyo, Japan, 9:Bristol-Myers Squibb, New Jersey, USA, 10:Shibukawa Medical Center, Shibukawa, Japan, 11:University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan

Impact of chromosomal abnormalities on the efficacy of lenalidomide treatment on multiple myeloma

[演者] Takashi Yoshida (吉田 嵩):1
[著者] Masaki Ri (李 政樹):1, Shiori Kinoshita (木下 史緒理):1, Haruhito Totani (戸谷 治仁):1, Yoshiaki Marumo (丸茂 義晃):1, Hirokazu Sasaki (佐々木 宏和):1, Takahiro Nakashima (中島 貴裕):1, Chie Kato (加藤 千絵):1, Takashi Kanamori (金森 貴之):1, Satsuki Murakami (村上 五月):1, Tomoko Narita (成田 朋子):1, Ayako Masaki (正木 彩子):1, Asahi Ito (伊藤 旭):1, Shigeru Kusumoto (楠本 茂):1, Takashi Ishida (石田 高司):1, Hirokazu Komatsu (小松 弘和):1, Shinsuke Iida (飯田 真介):1
1:Division of Hematology & Oncology, Nagoya City University Hospital, Nagoya, Japan

DRd vs Rd in Japanese patients with RRMM: Subgroup analysis of the phase 3 POLLUX study

[演者] Shinsuke Iida:1
[著者] Meletios A. Dimopoulos:2, Naoki Takezako:3, Kaida Wu:4, Xiang Qin:4, Ming Qi:4, Kenshi Suzuki:5
1:Nagoya City University Graduate School of Medical Sciences, Japan, 2:National and Kapodistrian University of Athens, Athens, Greece, 3:Department of Hematology, National Hospital Organization Disaster Medical Center of Japan, Tachikawa, Japan, 4:Janssen Research & Development, LLC, Spring House, PA, USA, 5:Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan

詳細検索